Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25540026 | 0.87 | THRB (0.38) | THRBSIGMAR1HSD11B1PTGDR2DRD2 | |
| SCHEMBL13808999 | 0.82 | MAPT (0.42) | THRBSIGMAR1HSD11B1PTGDR2DRD2 | |
| SCHEMBL18346708 | 0.80 | SIGMAR1 (0.38) | THRBSIGMAR1HSD11B1DRD2DRD3 | |
| SCHEMBL17831928 | 0.80 | SIGMAR1 (0.38) | THRBSIGMAR1HSD11B1DRD2DRD3 | |
| SCHEMBL21064697 | 0.80 | SIGMAR1 (0.38) | THRBSIGMAR1HSD11B1DRD2DRD3 | |
| SCHEMBL13895338 | 0.79 | SETD7 (0.41) | THRBSMN1; SMN2MAPTTSHRALDH1A1 | |
| SCHEMBL19504105 | 0.79 | SETD7 (0.41) | THRBSMN1; SMN2MAPTTSHRALDH1A1 | |
| SCHEMBL25873549 | 0.79 | SETD7 (0.41) | THRBSMN1; SMN2MAPTTSHRALDH1A1 | |
| SCHEMBL26112625 | 0.79 | SIGMAR1 (0.37) | THRBSIGMAR1HSD11B1PTGDR2DRD2 | |
| SCHEMBL26112622 | 0.79 | SIGMAR1 (0.37) | THRBSIGMAR1HSD11B1PTGDR2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | THRB 1742/4885SIGMAR1 1928/4885HSD11B1 2021/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | THRB 1742/4885SIGMAR1 1928/4885HSD11B1 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.